Erytech Pharma is a biopharmaceutical company developing therapies for various forms of cancer and orphan diseases. Utilizing its proprietary ERYCAPS platform, which uses a technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, Co. is developing a pipeline of product candidates for patients with unmet medical needs. Co.'s main product candidate, eryaspase, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. Co. is developing eryaspase for the treatment of cancer, including pancreatic cancer and triple negative breast cancer. The ERYP stock yearly return is shown above.
The yearly return on the ERYP stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ERYP annual return calculation with any dividends reinvested as applicable (on ex-dates).
|